bluuebunny/crossref_metadata_2025_split huggingface dataset:
APLIKASI ELECTRICAL ASSISTED OIL RECOVERY DI INDONESIA, SEBAGAI TEKNOLOGI ALTERNATIF UNTUK MENINGKATKAN PRODUKSI MINYAK NASIONAL
Authors: WITASTA NYOMAN , LUMBAN GAOL ARDHI HAKIM , TANGGU PATERNUS SYUKUR , WATTIMENA FRANS 
Published: July 2022

Produksi minyak Indonesia terus menurun karena lebih dari 70% lapangan yang berproduksi merupakan lapangan tua, umumnya sudah melewati puncak produksi, cadangannya menurun, dan kadar air mencapai di atas 90% dengan factor perolehan lebih dari 30%. Salah satu cara untuk meningkatkan produksi selanjutnya adalah dengan penerapan Enhanced Oil Recovery (EOR). Makalah ini menyajikan aplikasi teknologi untuk meningkatkan produksi minyak menggunakan Electric Assisted Oil Recovery (EAOR), metode yang baru dikembangkan di Indonesia. Dengan mengalirkan arus searah (DC) ke dalam reservoir, memanfaatkan satu sumur idle sebagai anode yang berfungsi sebagai injektor, dan satu sumur lainnya sebagai katode yang berfungsi sebagai sumur produksi. Tujuannya adalah mencari terobosan teknologi alternatif yang efisien untuk peningkatan produksi minyak nasional. Uji coba EAOR di Indonesia telah dilakukan sejak 2011 di Lapangan Klamono, Papua, dan berhasil meningkatkan produksi hingga 500%. Keberhasilan tersebut menjadi pemicu untuk terus melakukan uji coba di berbagai lapangan di Sumatera Selatan, Tarakan, Sumatera Tengah, Papua, dan Cepu. Secara statistik, uji coba EAOR secara keseluruhan berhasil meningkatkan produksi 35-40% dari baseline, menurunkan water cut, dan menurunkan viskositas minyak 15-20%. Saat ini, aplikasi EAOR terus berlanjut, dengan model berpola, mengoptimalkan satu unit EAOR untuk meningkatkan produksi 4-8 sumur di sekitar anoda. Model ini berhasil di beberapa lapangan pada reservoir batupasir dan karbonat. Dengan peningkatan produksi rata-rata 100 barel oil per hari (bopd) secara berpola atau klaster, dan 30-35 bopd per sumur, secara single well.. Peningkatan produksi kumulatif dari satu klaster mencapai 22.385 barel minyak. Kata Kunci : Anode, American Petroleum Institute, Direct Current Electrical EOR, Enhanced Oil Recovery, Electric Assisted Oil Recovery, Electrical Enhanced Oil Recovery, Katode, Viskositas.
Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors
Authors: Motloch Lukas J. , Jirak Peter , Mirna Moritz , Fiedler Lukas , Davtyan Paruir A. , Lakman Irina A. , Gareeva Diana F. , Tyurin Anton V. , Gumerov Ruslan M. , Matskeplishvili Simon T. , Pavlov Valentin N. , Cai Benzhi , Kopp Kristen , Topf Albert , Hoppe Uta C. , Pistulli Rudin , Zagidullin Naufal S. 
Published: July 2022

IntroductionCardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting.MethodsTo investigate this issue, we conducted a retrospective follow-up (393 ± 87 days) of 1,746 consecutive patients, hospitalized with and surviving COVID-19 pneumonia at a single tertiary medical center between April and December 2020. Survivors received either 30-day post-discharge antithrombotic treatment regime using prophylactic direct oral anticoagulation (DOAC; n = 1,002) or dipyridamole (n = 304), or, no post-discharge antithrombotic treatment (Ctrl; n = 440). All-cause mortality, as well as cardiovascular mortality (CVM) and further cardiovascular outcomes (CVO) resulting in hospitalization due to pulmonary embolism (PE), myocardial infarction (MI) and stroke were investigated during the follow-up period.ResultsWhile no major bleeding events occured during follow-up in the treatment groups, Ctrl showed a high but evenly distributed rate all-cause mortality. All-cause mortality (CVM) was attenuated by prophylactic DOAC (0.6%, P &lt; 0.001) and dipyridamole (0.7%, P &lt; 0.001). This effect was also evident for both therapies after propensity score analyses using weighted binary logistic regression [DOAC: B = −3.33 (0.60), P &lt; 0.001 and dipyridamole: B = −3.04 (0.76), P &lt; 0.001]. While both treatment groups displayed a reduced rate of CVM [DOAC: B = −2.69 (0.74), P &lt; 0.001 and dipyridamole: B = −17.95 (0.37), P &lt; 0.001], the effect in the DOAC group was driven by reduction of both PE [B−3.12 (1.42), P = 0.012] and stroke [B = −3.08 (1.23), P = 0.028]. Dipyridamole significantly reduced rates of PE alone [B = −17.05 (1.01), P &lt; 0.001].ConclusionLate cardiovascular events and all-cause mortality were high in the year following hospitalization for COVID-19. Application of prophylactic DOAC or dipyridamole in the early post-discharge period improved mid- and long-term CVO and all-cause mortality in COVID-19 survivors.
The relationship of remnant cholesterol and abdominal obesity in children: A cross-sectional study
Authors: Tong Jishuang , Li Xinggui , Liang Xiaoyue , Tang Fang , Ren Yanling , Hao Guang , Peng Xin , Luo Sunqing , Feng Ye , Huang Daochao , Zhao Li , Liang Xiaohua 
Published: July 2022

BackgroundPrevious studies found that remnant cholesterol (RC) is a risk factor for cardiovascular diseases and childhood obesity is associated with cardiometabolic diseases. This study aimed to explore the relationship between RC and abdominal obesity in children.MethodsA total of 5,959 children, aged 6−12 years old, were selected from a cross-sectional study in urban-rural areas of Chongqing, China. RC was calculated by total cholesterol (TC)—high-density lipoprotein (HDL-C) cholesterol—low-density lipoprotein (LDL-C) cholesterol and was divided into four groups by quartiles (Q1–Q4).ResultsCompared to children with the lowest RC (Q1), children with higher RC had significantly higher odds of abdominal obesity (Q2: OR = 1.450, 95% CI: 1.131−1.859, p &lt; 0.05; Q3: OR = 2.127, 95% CI: 1.632−2.772, p &lt; 0.001; Q4: OR = 2.386, 95% CI: 1.819−3.130, p &lt; 0.001). In the stratified analyses by urban-rural areas, the odds ratios were greater in rural areas (Q2: OR = 2.228, 95% CI: 1.572−3.160, p &lt; 0.001; Q3: OR = 3.668, 95% CI: 2.191−6.140, p &lt; 0.001; Q4: OR = 6.490, 95% CI: 2.271−18.551, p &lt; 0.001) than in urban areas (Q2: OR = 1.644, 95% CI: 1.192−2.266, p &lt; 0.05; Q3: OR = 2.266, 95% CI: 1.667−3.082, p &lt; 0.001; Q4: OR = 2.711, 95% CI: 2.005−3.665, p &lt; 0.001).ConclusionsOur study found that RC was positively correlated with abdominal obesity in children, and this association was higher for children living in rural areas.
Effectiveness and safety of oral anticoagulant therapy in patients with atrial fibrillation with prior gastrointestinal bleeding: A systematic review and meta-analysis
Authors: Zhao Jie , Wu Xiaojuan , Li Siyuan , Gu Qiuping 
Published: July 2022

BackgroundGastrointestinal bleeding (GIB) commonly complicates anticoagulant therapy for patients with atrial fibrillation (AF). However, AF patients with prior GIB were excluded from most randomized controlled trials on anticoagulation therapy. Therefore, we conducted a systematic review and meta-analysis to assess the effect of oral anticoagulant (OAC) therapy in this specific population.MethodsRandomized trials and observational studies reporting the data about the resumption of OAC therapy among AF patients with prior GIB were included. The search was performed in the PubMed and Embase databasesup to March 2022. The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled by a random-effects model with an inverse variance method.ResultsA total of 7 studies involving 57,623 patients were included. Compared with no anticoagulant therapy, OAC therapy was associated with decreased risks of stroke or systemic embolism (HR = 0.71, 95% CI: 0.59–0.84) and all-cause death (HR = 0.66, 95% CI: 0.60–0.72), but there was no significant difference in the risk of recurrent GIB (HR = 1.22, 95% CI: 0.94–1.59). Compared with vitamin K antagonists, non-vitamin K antagonist oral anticoagulants (NOACs) were associated with reduced risks of stroke or systemic embolism (HR = 0.61, 95% CI: 0.54–0.68), all-cause mortality (HR = 0.86, 95% CI: 0.75–0.99), major bleeding (HR = 0.75, 95% CI: 0.66–0.84), and GIB recurrence (HR = 0.83, 95% CI: 0.72–0.96).ConclusionsIn AF patients with prior GIB, OAC therapy (especially NOACs) demonstrated superior effectiveness compared with no anticoagulant therapy.
Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
Authors: Wulamiding Kaisaier , Xu Zixuan , Chen Yili , He Jiangui , Wu Zexuan 
Published: July 2022

BackgroundPatient prevalence of atrial fibrillation (AF) and heart failure (HF) is increasing, and anticoagulation for patients from heterogeneous backgrounds with both conditions remains controversial. In this meta-analysis, we are aiming to compare the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in AF patients with HF and preserved (HFpEF), mildly reduced (HFmrEF), and reduced (HFrEF) ejection fraction.Methods and resultsWe systematically searched the PubMed, Cochrane, and Embase databases until January 2022. The primary effectiveness and safety outcomes were stroke or systemic embolism (SSE) and major bleeding, respectively. We abstracted risk ratios (RR) and 95% confidence intervals (CIs) and compiled them using a random-effects model. We analyzed data of 266,291 patients from 10 studies. By comparing NOACs with warfarin, patients with AF and HF have reduced the risk of SSE (RR: 0.83, 95% CI 0.76–0.91), all-cause mortality (RR: 0.85, 95% CI 0.80–0.91), major bleeding (RR: 0.79, 95% CI 0.69–0.90), and intracranial hemorrhage (RR: 0.54, 95% CI 0.46–0.63). Further analyses based on the HF subtypes showed that NOACs reduced the chances of SSE (RR: 0.71, 95% CI 0.53–0.94) in the HFrEF group and major bleeding (RR: 0.74, 95% CI 0.57–0.95) in HFmrEF and HFpEF groups. There were no differences regarding SSE (RR: 0.91, 95% CI 0.76–1.09) in HFmrEF and HFpEF groups and major bleeding (RR: 0.99, 95% CI 0.79–1.23) in the HFrEF group.ConclusionFor patients with AF and HF, NOACs have better or similar effectiveness and safety than warfarin, but the stroke prevention superiority of NOACs over warfarin varies in different HF subtypes.
The different structure-function correlation as measured by OCT and octopus perimetry cluster analysis in intracranial tumor and glaucoma patients
Authors: Li Xiaochun , Qin Jiayin , Cao Xiaoguang , Ren Zeqin , Cui Ting , Bao Yongzhen 
Published: July 2022

BackgroundTo explore the correlation between visual field (VF) defect values and retinal nerve fiber layer (RNFL) thickness for intracranial tumor and glaucoma patients.MethodsRetrospective analysis is performed for the intracranial and glaucoma patients, whose VF defect values were measured with Octopus perimeter cluster analysis, RNFL thickness, ganglion cell layer (GCL) thickness, and optic disk parameters measured with swept-source OCT. The differences between VF and RNFL (including the data of optic disc) are calculated. The correlation between VF defect values and RNFL and GCL thickness are explored.ResultsIn total 43 eyes of 29 patients with intracranial tumor and 31 eyes of 19 patients with glaucoma were enrolled. The thickness of RNFL not only for the whole (360°), but also for the four quadrants was thinner in the glaucoma group than those of the intracranial tumor group (p&lt;0.05), and similar to the thickness of GCL without significance (p&gt;). There is no significant difference in VF for those two groups except glaucoma having lower sLV (p&lt;0.05). A stronger correlation for mean deviations (MD)s of VF ten clusters and RNFL thickness of OCT twelve sectors is found in the glaucoma patients, but few in the intracranial tumor patients. Logistic regression also shows the loss of RNFL or increasing of vertical CDR and cup volume tending to the diagnosis of glaucoma and the irregular VF damage is inclined to the diagnosis of intracranial tumor.ConclusionsIntracranial tumor has a weak correlation between the RNFL thickness and Octopus VF MD, compared with that of glaucoma. OCT and Octopus VF might provide more helpful information for the differential diagnosis of intracranial tumor and glaucoma.
Safety and efficacy of ultrasound-guided thermal ablation in treating T1aN0M0 and T1bN0M0 papillary thyroid carcinoma: A meta-analysis
Authors: Wang Mei-Huan , Liu Xiao , Wang Qian , Zhang Hua-Wei 
Published: July 2022

BackgroundPapillary thyroid cancer (PTC) is the most common thyroid tumor, and early diagnosis and treatment can effectively improve prognosis. Many controversies surround the treatment method of T1N0M0 PTC. Recently, thermal ablation (TA) has shown some benefits in the treatment of PTC patients, but the safety and efficacy of its treatment remain controversial. This article performs a meta-analysis of TA in patients with T1aN0M0 and T1bN0M0 PTC.MethodsThe PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched for retrospective or prospective studies of TA for treating patients with T1N0M0 PTC from the database establishment to May 1, 2022. Data on volume reduction rate (VRR), disease progress, and complication rate were collected. In addition, a meta-analysis was performed using the Stata 12.0 and Review Manager 5.3.ResultsA total of 9 eligible studies were included. Our study demonstrated the effectiveness of VRR and disease progress. The VRR was reduced after 3 months (−75.90%; 95% CI [−118.46–33.34%]), 6 months (34.33%; 95% CI [15.01–53.65%]), 12 months (78.69%; 95% CI [71.69–85.68%]), and 24 months (89.97%; 95% CI [84.00–95.94%]). The disease progress was 1.9% (95% CI [1.1–3.0]). Safety is justified by the complication rate, which was 6.5% (95% CI [3.5–10.2]). Pain and hoarseness were the most common complications, and no life-threatening complications were reported. Egger’s test demonstrated that publication bias was acceptable.ConclusionsTA is an effective and safe method for managing T1aN0M0 and T1bN0M0 papillary thyroid nodules.
A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Boccard Mathilde , Conrad Anne , Mouton William , Valour Florent , Roure-Sobas Chantal , Frobert Emilie , Rohmer Barbara , Alcazer Vincent , Labussière-Wallet Hélène , Ghesquières Hervé , Venet Fabienne , Brengel-Pesce Karen , Trouillet-Assant Sophie , Ader Florence 
Published: July 2022

Herpes zoster, which is due to the reactivation of Varicella zoster virus (VZV), is a leading cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While cell-mediated immunity (CMI) is critical to inhibiting VZV reactivation, CMI is not routinely assessed due to a lack of reliable tests. In this study, we aimed to evaluate VZV-specific CMI among allo-HSCT recipients (n = 60) and healthy individuals (HI, n = 17) through a panel of three immune functional assays after ex vivo stimulation by VZV antigen: quantification of (i) IFN-γ release in the supernatants, (ii) T-cell proliferation after a 7-day stimulation of peripheral blood mononuclear cells (PBMC), and (iii) measurement of the ifn-γ mRNA gene expression level after 24 h of stimulation of a whole-blood sample. VZV responsiveness was defined according to IFN-γ release from VZV-stimulated PBMC. Upon VZV stimulation, we found that allo-HSCT recipients at a median time of 6 [5-8] months post-transplant had lower IFN-γ release (median [IQR], 0.34 [0.12–8.56] vs. 409.5 [143.9–910.2] pg/ml, P &lt;.0001) and fewer proliferating T cells (0.05 [0.01–0.57] % vs. 8.74 [3.12–15.05] %, P &lt;.0001) than HI. A subset of allo-HSCT recipients (VZV-responders, n = 15/57, 26%) distinguished themselves from VZV-non-responders (n = 42/57, 74%; missing data, n = 3) by higher IFN-γ release (80.45 [54.3–312.8] vs. 0.22 [0.12–0.42] pg/ml, P &lt;.0001) and T-cell proliferation (2.22 [1.18–7.56] % vs. 0.002 [0.001–0.11] %, P &lt;.0001), suggesting recovery of VZV-specific CMI. Interestingly, VZV responders had a significant fold increase in ifn-γ gene expression, whereas ifn-γ mRNA was not detected in whole blood of VZV-non-responders (P &lt;.0001). This study is the first to suggest that measurement of ifn-γ gene expression in 24-h-stimulated whole blood could be an accurate test of VZV-specific CMI. The routine use of this immune functional assay to guide antiviral prophylaxis at an individual level remains to be evaluated.
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
Authors: Zhou Chengzhi , Yang Yilin , Lin Xinqing , Fang Nianxin , Chen Likun , Jiang Juhong , Deng Haiyi , Deng Yu , Wan Minghui , Qiu Guihuan , Sun Ni , Wu Di , Long Xiang , Zhong Changhao , Xie Xiaohong , Xie Zhanhong , Liu Ming , Ouyang Ming , Qin Yinyin , Petrella Francesco , Fiorelli Alfonso , Bravaccini Sara , Kataoka Yuki , Watanabe Satoshi , Goto Taichiro , Solli Piergiorgio , Igai Hitoshi , Saito Yuichi , Tsoukalas Nikolaos , Nakada Takeo , Li Shiyue , Chen Rongchang 
Published: July 2022

BackgroundCheckpoint inhibitor–related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.MethodsWe conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase’s characteristics.ResultsThere were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: ≥13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased (P&lt;0.05). The main change in radiologic features was the absorption of the lesions, and 3 (3/11) patients in the chronic phase had persistent traction bronchiectasis. For histologic features, most patients had acute fibrinous pneumonitis in the acute phase (5/8), and most had organizing pneumonia in the subacute phase (5/6). Other histologic changes advanced over time, with the lesions entering a state of fibrosis. Moreover, the levels of interleukin-6, interleukin-10 and high-sensitivity C-reactive protein (hsCRP) increased in the acute phase and decreased as CIP progressed (IL-6: 17.9 vs. 9.8 vs. 5.7, P=0.018; IL-10: 4.6 vs 3.0 vs. 2.0, P=0.041; hsCRP: 88.2 vs. 19.4 vs. 14.4, P=0.005).ConclusionsThe general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.
CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma
Authors: Liu Long , Liu Zaoqu , Gao Jie , Liu Xudong , Weng Siyuan , Guo Chunguang , Hu Bowen , Wang Zhihui , Zhang Jiakai , Shi Jihua , Guo Wenzhi , Zhang Shuijun 
Published: July 2022

IntroductionMounting evidence has revealed that the interactions and dynamic alterations among immune cells are critical in shaping the tumor microenvironment and ultimately map onto heterogeneous clinical outcomes. Currently, the underlying clinical significance of immune cell evolutions remains largely unexplored in hepatocellular carcinoma (HCC).MethodsA total of 3,817 immune cells and 1,750 HCC patients of 15 independent public datasets were retrieved. The Seurat and Monocle algorithms were used to depict T cell evolution, and nonnegative matrix factorization (NMF) was further applied to identify the molecular classification. Subsequently, the prognosis, biological characteristics, genomic variations, and immune landscape among distinct clusters were decoded. The clinical efficacy of multiple treatment approaches was further investigated.ResultsAccording to trajectory gene expression, three heterogeneous clusters with different clinical outcomes were identified. C2, with a more advanced pathological stage, presented the most dismal prognosis relative to C1 and C3. Eight independent external cohorts validated the robustness and reproducibility of the three clusters. Further explorations elucidated C1 to be characterized as lipid metabolic HCC, and C2 was referred to as cell-proliferative HCC, whereas C3 was defined as immune inflammatory HCC. Moreover, C2 also displayed the most conspicuous genomic instability, and C3 was deemed as “immune-hot”, having abundant immune cells and an elevated expression of immune checkpoints. The assessments of therapeutic intervention suggested that patients in C1 were suitable for transcatheter arterial chemoembolization treatment, and patients in C2 were sensitive to tyrosine kinase inhibitors, while patients in C3 were more responsive to immunotherapy. We also identified numerous underlying therapeutic agents, which might be conducive to clinical transformation in the future.ConclusionsOur study developed three clusters with distinct characteristics based on immune cell evolutions. For specifically stratified patients, we proposed individualized treatment strategies to improve the clinical outcomes and facilitate the clinical management.
Serial negative response after standard and third (Booster) dose of COVID-19 inactivated vaccine is associated with low vitamin D levels in patients with solid cancers
Authors: Ma Yifei , Zhu Pengfei , Zhong Guanqing , Wang Dao , Cao Lu , Bai Shenrui , Wang Youlong , Zhang Ao , Wang Xinjia 
Published: July 2022

IntroductionThe response is poorly understood to the third dose in patients with cancer who failed the standard dose of inactivated SARS-CoV-2 vaccines (CoronaVac). We aim to assess the immune response to the third dose and identify whether vitamin D deficiency is associated with serial serologic failure in patients with cancer.MethodsSolid cancer patients (SCP-N) and healthy controls (HCs) who were seronegative after the standard-dose vaccines in our previous study were prospectively recruited, from October 2021 to February 2022, to receive the third dose vaccines and anti-SARS-CoV-2S antibodies were measured. SCP-N who failed the third dose (serial seronegative group, SSG) were matched by propensity scores with the historical standard-dose positive cancer patient group (robust response group, RRG). An exploratory analysis was carried out to validate the role of vitamin D on the serology response.ResultsThe multi-center study recruited 97 SCP-N with 279 positive controls as RRG and 82 negative controls as HC group. The seroconversion rate after third-dose vaccination was higher in SCP-N than in HC (70.6% vs. 29.4%, p &lt; 0.01). The matched comparison showed that patients in SSG had a significantly lower level of vitamin D and consumption rate than RRG or RRG-B (RRG with third-dose positive) (all p &lt; 0.01). None had serious (over grade II) adverse events after the third dose.ConclusionSolid cancer patients with second-dose vaccine failure may have a relatively poor humoral response to the third dose of COVID-19 vaccines as compared with the seronegative HC group. The consecutively poor humoral response could be associated with poor vitamin D levels and intake. Vitamin D status and cancer-related immune compromise may jointly affect the humoral response following booster vaccination.